Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Non-Tech : Kirk's Market Thoughts -- Ignore unavailable to you. Want to Upgrade?

To: Kirk © who wrote (14050)	6/14/2022 3:04:11 PM
From: w0z	Respond to of 26417

"not the rate for the percentage of people in that age group that get COVID." Another unknown is exactly where people were in covid progression. Because the zinc ionophore/zinc addresses replication of the virus, it works better at the earliest stages of disease progression. The study stated: "experiencing 2 or more symptoms of acute infection for <=7 days" I'd be interested to know their definition of acute. To me that would indicate severe, which would imply advanced progression. IVM definitely works best in the earliest stages of virus replication, in fact even better when used as a prophylactic (e.g. two lowest doses weekly). My wife's doc does not accept Medicare and offers a concierge service. He's available 24X7X365 by text or phone and even makes housecalls. I believe most of his patients were treated in the very early stages (not hospitalized), when IVM/HCQ/Quercetin plus zinc is most effective. "Of course, many of us might have healthy zinc levels already from eating and taking vitamins to help fight illness like COVID." Good point! My vitamin D3 level has been maxed out for >10 years, selenium at 200 mcg/day, quercetin/zinc/chelated copper began March 2020, all before adding IVM in October 2020. It could well be that IVM is redundant, but at $53/year for both of us, it's cheap insurance.